going off tirzepatide COMING RETATRUTIDE: THE PART MOST PEOPLE IGNORE, Retatrutide can produce dramatic weight loss. In Eli Lilly’s Phase 3 TRIUMPH-1 trial, the 12 mg group lost an average of 28.3% body weight over 80 Do You Have to Taper

Subcutaneous injection into abdominal tissue achieves systemic distribution without introducing infection risk near vulnerable joint structures

Side Effects & Safety What are the common side effects

Veldhuis JD, Roelfsema F

Since glucagon stimulates hepatic glucose production, its reduction leads to less activation of gluconeogenic pathways in the liver

In this context, glucagon-like peptide-1 receptor (GLP-1R) agonists have been increasingly used in the treatment of pediatric obesity, with evidence supporting their efficacy in reducing body weight, BMI, and improving glycemic control, although gastrointestinal side effects, such as nausea, are common